DrugPatentWatch Database Preview
Alvogen Company Profile
What is the competitive landscape for ALVOGEN, and what generic alternatives to ALVOGEN drugs are available?
ALVOGEN has fifty-two approved drugs.
There is one US patent protecting ALVOGEN drugs. There is one tentative approval on ALVOGEN drugs.
There is one patent family member on ALVOGEN drugs in one country and one hundred and forty-six supplementary protection certificates in fourteen countries.
Summary for Alvogen
| International Patents: | 1 |
| US Patents: | 1 |
| Tradenames: | 47 |
| Ingredients: | 44 |
| NDAs: | 52 |
| Patent Litigation for Alvogen: | See patent lawsuits for Alvogen |
| PTAB Cases with Alvogen as petitioner: | See PTAB cases with Alvogen as petitioner |
Drugs and US Patents for Alvogen
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alvogen | NAPRELAN | naproxen sodium | TABLET, EXTENDED RELEASE;ORAL | 020353-003 | Jan 5, 1996 | AB | RX | Yes | Yes | Start Trial | Start Trial | ||||
| Alvogen | NAPRELAN | naproxen sodium | TABLET, EXTENDED RELEASE;ORAL | 020353-001 | Jan 5, 1996 | AB | RX | Yes | No | Start Trial | Start Trial | ||||
| Alvogen | THYRO-TABS | levothyroxine sodium | TABLET;ORAL | 021116-002 | Oct 24, 2002 | AB2,AB4 | RX | Yes | No | Start Trial | Start Trial | ||||
| Alvogen Inc | ACETYLCYSTEINE | acetylcysteine | SOLUTION;INHALATION, ORAL | 204674-001 | Feb 11, 2014 | AN | RX | No | No | Start Trial | Start Trial | ||||
| Alvogen Inc | CLINDAMYCIN PHOSPHATE | clindamycin phosphate | INJECTABLE;INJECTION | 062943-001 | Sep 29, 1988 | AP | RX | No | No | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Alvogen
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Alvogen | ZESTORETIC | hydrochlorothiazide; lisinopril | TABLET;ORAL | 019888-003 | Nov 18, 1993 | 4,472,380 | Start Trial |
| Alvogen | TENORMIN | atenolol | TABLET;ORAL | 018240-001 | Approved Prior to Jan 1, 1982 | 3,663,607 | Start Trial |
| Alvogen | ZESTRIL | lisinopril | TABLET;ORAL | 019777-004 | May 19, 1988 | 4,374,829*PED | Start Trial |
| Alvogen | TENORMIN | atenolol | TABLET;ORAL | 018240-002 | Approved Prior to Jan 1, 1982 | 3,934,032 | Start Trial |
| Alvogen | NAPRELAN | naproxen sodium | TABLET, EXTENDED RELEASE;ORAL | 020353-001 | Jan 5, 1996 | 5,637,320 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ALVOGEN drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Tablets | 450 mg | ➤ Subscribe | 2013-02-28 |
International Patents for Alvogen Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2008038155 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Alvogen Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0206283 | 98C0041 | Belgium | Start Trial | PRODUCT NAME: LEVOFLOXACINUM HEMIHYDRICUM; NAT. REGISTRATION NO/DATE: 354 IS 370 F3 19980624; FIRST REGISTRATION: GB 134020011 19970606 |
| 0206283 | SPC/GB97/085 | United Kingdom | Start Trial | PRODUCT NAME: LEVOFLOXACIN, OPTIONALLY IN THE FORM OF A HEMIHYDRATE; REGISTERED: UK 13402/0011 19970606; UK 13402/0012 19970606; UK 13402/0013 19970606 |
| 0770388 | PA2009004,C0770388 | Lithuania | Start Trial | PRODUCT NAME: ESTRADIOLI VALERAS + DIENOGESTUM; NAT. REGISTRATION NO/DATE: LT/1/09/1512/001, 2009 04 06 LT/1/09/1512/002, 2009 04 06 LT/1/09/1512/003 20090406; FIRST REGISTRATION: BE 327792 20081103 |
| 0984957 | PA2011005,C0984957 | Lithuania | Start Trial | PRODUCT NAME: NAPROXENUM + ESOMEPRAZOLUM; REGISTRATION NO/DATE: LT/1/10/2302/001-LT/1/10/2302/012 20110126 |
| 0771217 | CA 2006 00038 | Denmark | Start Trial | PRODUCT NAME: ETHINYLESTRADIOL (SOM BETA-CYCLODEXTRIN-CLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 38687 20060627; FIRST REG. NO/DATE: EU RVG 31781 20050804 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
